fintols

Pfizer vs Sanofi (PFE vs SAN.PA)

Sanofi trades at 24.3x earnings vs 40.1x for Pfizer; Sanofi grows sales faster (+15.7% vs -0.4%). Margins, debt and dividend, Nov 2026.

Quick answer

On today's data (November 19, 2026): Sanofi looks cheaper on P/E: 24.3x against 40.1x for Pfizer. Sanofi grows faster: sales +15.7% against -0.4% for Pfizer in the latest quarter. Sanofi has the better net margin: 8.2% against 6.3% for Pfizer.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Pfizer freeAnalyze Sanofi free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Pfizer is the more expensive of the two: it trades at 40.1x its annual earnings against 24.3x for Sanofi. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. What helps read that gap: Pfizer sales -0.4% against +15.7% for Sanofi in the latest quarter; net margin 6.3% against 8.2%; net debt for Pfizer: 2.0x EBITDA against 0.9x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Pfizer (PFE) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Pfizer and Sanofi side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Pfizer or Sanofi.

Pfizer vs Sanofi: the figures

FigurePfizerSanofi
Share price$28.06 (November 18, 2026)€84.08 (November 19, 2026)
Market cap$159.9 billion€100.9 billion
P/E (TTM)40.1x24.3x
Forward P/E9.5x8.8x
Revenue growth (quarter)-0.4%+15.7%
Net margin (TTM)6.3%8.2%
Net debt / EBITDA2.0x0.9x
Dividend yield6.13%4.76%
Beta0.300.26

Pfizer and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Pfizer or Sanofi figure is not available, and we never estimate it.

3 key differences between Pfizer and Sanofi

  1. Valuation: Pfizer trades at 40.1x its annual earnings and Sanofi at 24.3x; the market pays more for each dollar of Pfizer profit, usually because it expects more growth.
  2. Growth: Sanofi grew sales +15.7% year on year in its latest quarter, against -0.4% for Pfizer.
  3. Dividend: Pfizer yields 6.13% at today's price and Sanofi yields 4.76%.

Pfizer or Sanofi: which fits your profile

Neither Pfizer nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Pfizer or Sanofi?

Of the 6 comparable figures in the table, Pfizer stands out on 1 (dividend yield) and Sanofi stands out on 5 (sales growth, net margin, lower P/E, less debt over EBITDA and lower volatility (beta)). That does not name a winner between Pfizer and Sanofi: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Pfizer vs Sanofi (PFE vs SAN.PA)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze PFE free